MARKET

AGTC

AGTC

AGTC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.870
-0.110
-3.69%
Closed 16:00 12/06 EST
OPEN
2.990
PREV CLOSE
2.980
HIGH
3.070
LOW
2.870
VOLUME
110.12K
TURNOVER
--
52 WEEK HIGH
6.87
52 WEEK LOW
2.260
MARKET CAP
52.29M
P/E (TTM)
-3.5116
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of AGTC and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

AGTC News

  • Edited Transcript of AGTC earnings conference call or presentation 12-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.2d ago
  • Applied Genetics Technology Corporation: Strong Science And Clinical Efficacy
  • Seeking Alpha - Article.3d ago
  • The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial
  • Benzinga.3d ago
  • The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial
  • Benzinga.3d ago

More

Industry

Biotechnology & Medical Research
+1.28%
Pharmaceuticals & Medical Research
+0.68%

Hot Stocks

Name
Price
%Change

About AGTC

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and reduced or complete loss of color discrimination, achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).
More

Webull offers Applied Genetic Technologies Corp (AGTC) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.